Current Treatment Options and Emerging Agents for Schizophrenia

被引：0

作者：

Correll, Christoph U. ^{[1
,2
,3
]}

机构：

[1] Zucker Hillside Hosp, Dept Psychiat, Glen Oaks, NY 11004 USA

[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Psychiat & Mol Med, Hempstead, NY 11549 USA

[3] Charite, Dept Child & Adolescent Psychiat, Berlin, Germany

来源：

JOURNAL OF CLINICAL PSYCHIATRY | 2020年 / 81卷 / 03期

关键词：

ACTING INJECTABLE ANTIPSYCHOTICS; DOUBLE-BLIND; SODIUM-NITROPRUSSIDE; 2ND-GENERATION ANTIPSYCHOTICS; TARDIVE-DYSKINESIA; PSYCHOTIC SYMPTOMS; METAANALYSIS; CLOZAPINE; COGNITION; ITI-007;

D O I：

暂无

中图分类号：

B849 [应用心理学];

学科分类号：

040203 ;

摘要：

引用

页数：10

共 44 条

[1]

[Anonymous], 2019, SCHIZOPHR B S2

[2] Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia [J].

Bitter, Istvan ;

Lieberman, Jeffrey A. ;

Gaudoux, Florence ;

Sokoloff, Pierre ;

Groc, Melanie ;

Chavda, Rajeev ;

Delsol, Cecile ;

Barthe, Laurence ;

Brunner, Valerie ;

Fabre, Carine ;

Fagard, Marine ;

Montagne, Agnes ;

Tonner, Francoise .

NEUROPSYCHOPHARMACOLOGY, 2019, 44 (11) :1917-1924

[3] The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial [J].

Boggs, Douglas L. ;

Surti, Toral ;

Gupta, Aarti ;

Gupta, Swapnil ;

Niciu, Mark ;

Pittman, Brian ;

Martin, Ashley M. Schnakenberg ;

Thurnauer, Halle ;

Davies, Andrew ;

D'Souza, Deepak C. ;

Ranganathan, Mohini .

PSYCHOPHARMACOLOGY, 2018, 235 (07) :1923-1932

[4] Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial [J].

Brown, Hannah E. ;

Freudenreich, Oliver ;

Fan, Xiaoduo ;

Heard, Stephen O. ;

Goff, Donald ;

Petrides, George ;

Harrington, Amy L. ;

Kane, John M. ;

Judge, Heidi ;

Hoeppner, Bettina ;

Fava, Maurizio ;

Perlis, Roy H. .

JAMA PSYCHIATRY, 2019, 76 (07) :691-699

[5] A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia [J].

Carabias, Lourdes A. ;

Llaudo, Jordi ;

Ayani, Ignacio ;

Martinez, Javier ;

Litman, Robert E. ;

Gutierro, Ibon .

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (02) :79-87

[6] Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis [J].

Carbon, Maren ;

Kane, John M. ;

Leucht, Stefan ;

Correll, Christoph U. .

WORLD PSYCHIATRY, 2018, 17 (03) :330-340

[7]

Carbon M, 2014, DIALOGUES CLIN NEURO, V16, P505

[8]

Citrome L., 2018, CLIN SCHIZOPHR RELAT, V12, P130, DOI [DOI 10.3371/CSRP.CI.101118, 10.3371/CSRP.CI.101118]

[9] Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial [J].

Correll, Christoph U. ;

Sikich, Linmarie ;

Reeves, Gloria ;

Johnson, Jacqueline ;

Keeton, Courtney ;

Spanos, Marina ;

Kapoor, Sandeep ;

Bussell, Kristin ;

Miller, Leslie ;

Chandrasekhar, Tara ;

Sheridan, Eva M. ;

Pirmohamed, Sara ;

Reinblatt, Shauna P. ;

Alderman, Cheryl ;

Scheer, Abigail ;

Borner, Irmgard ;

Bethea, Terrence C. ;

Edwards, Sarah ;

Hamer, Robert M. ;

Riddle, Mark A. .

WORLD PSYCHIATRY, 2020, 19 (01) :69-80

[10] What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? [J].

Correll, Christoph U. ;

Rubio, Jose M. ;

Kane, John M. .

WORLD PSYCHIATRY, 2018, 17 (02) :149-160

← 1 2 3 4 5 →